Loading clinical trials...
Loading clinical trials...
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women. The overall goal is to bridge 9vHPV efficacy findings ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Merck Sharp & Dohme LLC
NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more
NCT07192055 · Anal Cancer
NCT04094454 · Anal Cancer
NCT05639972 · HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, and more
NCT06640283 · HPV-Related Carcinoma, Uterine Cervical Cancer, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions